Nafamostat mesilate as anticoagulant for blood purification: a systematic review and meta-analysis

NM is a safe and effective anticoagulant for blood purification, showing lower bleeding risk than conventional anticoagulants and longer filter life than NA, which is particularly suitable for patients at high risk of bleeding.

Authors

Institutions

Publication Details

Journal
Critical Care
Published
2025-12-24
DOI
https://doi.org/10.1186/s13054-025-05813-w
Primary Topic
Atrial Fibrillation Management and Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Nafamostat mesilate as anticoagulant for blood purification: a systematic review and meta-analysis

Xue Tang, Caihong Liu, Yuliang Zhao, Yingying Yang et al.
Critical Care
Atrial Fibrillation Management and Outcomes
article

Nafamostat mesilate as anticoagulant for blood purification: a systematic review and meta-analysis

Xue Tang, Caihong Liu, Yuliang Zhao, Yingying Yang, LH Zhang, Jinglei Ren, Fang Wang, Wei Wei, Xu Li, Ping Fu, Yongxiu Huang
article en

Abstract

NM is a safe and effective anticoagulant for blood purification, showing lower bleeding risk than conventional anticoagulants and longer filter life than NA, which is particularly suitable for patients at high risk of bleeding.

Critical CareVol. 30(1)
Sichuan University (CN), West China Hospital of Sichuan University (CN)
Zero hunger
Openalex Percentile: Top 31%
Atrial Fibrillation Management and Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.